Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease

American Journal of Cardiology

Volumn 83, Issue 9 B, 1999, Pages

  Brewer Jr, H Bryan ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY RISK; DISEASE ASSOCIATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0345620788     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00308-2     Document Type: Conference Paper

References (116)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Am J Cardiol. 344:1994;1383-1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
4. Rifkind B.M. Clinical trials of reducing low-density lipoprotein concentrations. Endocrinol Metab Clin North Am. 27:1998;585-595.
5. Forrester J.S., Merz C.N., Bush T.L., Cohn J.N., Hunninghake D.B., Parthasarathy S., Superko H.R. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol. 27:1996;991-1006.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
7. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622.
8. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation. 97:1998;1436-1439.
9. Genest J.J. Jr, Martin-Munley S.S., McNamara J.R., Ordovas J.M., Jenner J., Myers R.H., Silberman S.R., Wilson P.W.F., Salem D.N., Schaefer E.J. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85:1992;2025-2033.
10. Gianturco S.H., Bradley W.A., Gotto A.M. Jr, Morrisett J.D., Peavy D.L. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J Clin Invest. 70:1982;168-178.
11. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., Gotto A.M. Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 12:1992;1336-1345.
12. Karpe F., Steiner G., Uffelman K., Olivecrona T., Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 106:1994;83-97.
13. Hodis H.N., Mack W.J. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 6:1995;209-214.
14. Davignon J., Cohn J.S. Triglycerides a risk factor for coronary heart disease . Atherosclerosis. 124:(suppl S):1996;S57-S64.
15. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 81:1998;13B-17B.
16. Assmann G., Schulte H., Funke H., von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 19:(suppl M):1998;M8-M14.
17. Sprecher D.L. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol. 82:1998;49U-56U.
18. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 81:1998;7B-12B.
19. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 81:1998;18B-25B.
20. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen Male Study . Circulation. 97:1998;1029-1036.
21. Brunzell J.D. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 1995;1913-1932 McGraw-Hill, Inc, New York.
22. Brunzell J.D., Schrott H.G., Motulsky A.G., Bierman E.L. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism. 25:1976;313-320.
23. Brewer H.B. Jr, Santamarina-Fojo S., Hoeg J.M. Disorders of lipoprotein metabolism. DeGroot L.J., Besser M., Jameson J.L., Loriaux D., Marshall J.C., Odell W.D., Potts J.T. Jr, Rubenstein A.H., Cahill G.F. Jr, Martini L., Nelson D.H. Endocrinology. 1995;2731-2753 WB Saunders, Philadelphia.
24. Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer HB, Jr. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York:McGraw-Hill (In press).
25. Herz J., Hamann U., Rogne S., Myklebost O., Gausepohl H., Stanley K.K. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as a lipoprotein receptor. EMBO J. 7:1988;4119-4127.
26. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors macrophage scavenger receptor and LDL receptor-related protein (LRP) . Annu Rev Biochem. 63:1994;601-637.
27. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 17:1997;3542-3556.
28. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8:1988;1-21.
29. Goldstein J.L., Brown M.S., Anderson R.G., Russell D.W., Schneider W.J. Receptor-mediated endocytosis concepts emerging from the LDL receptor system . Annu Rev Cell Biol. 1:1985;1-39.
30. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 320:1989;915-924.
31. Glomset J.A., Janssen E.T., Kennedy R., Dobbins J. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res. 7:1966;638-648.
32. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 9:1968;155-167.
33. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res. 36:1995;211-228.
34. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res. 34:1993;1255-1274.
35. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:1996;518-520.
36. Krieger M. The other side of scavenger receptors pattern recognition for host defense . Curr Opin Lipidol. 8:1997;275-280.
37. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of apoA- and apoB-containing lipoprotein families. Progr Lipid Res. 30:1991;105-138.
38. Carlson L.A., Ballantyne D. Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia. Atherosclerosis. 23:1976;563-568.
39. Le N.A., Gibson J.C., Ginsberg H.N. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins implications for the regulation of the catabolism of these lipoproteins . J Lipid Res. 29:1988;669-677.
40. Windler E., Chao Y., Havel R.J. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem. 255:1980;8303-8307.
41. Quarfordt S.H., Michalopoulos G., Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 257:1982;14642-14647.
42. Ginsberg H.N., Le N.A., Goldberg I.J., Gibson J.C., Rubinstein A., Wang-Iverson P., Norum R., Brown W.V. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 78:1986;1287-1295.
43. Maeda N., Li H., Lee D., Oliver P., Quarfordt S.H., Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 269:1994;23610-23616.
44. Ito Y., Azrolan N., O'Connell A., Walsh A., Breslow J.L. Hypertriglyceridemia as a result of human apolipoprotein C-III gene expression in transgenic mice. Science. 249:1990;790-793.
45. Aalto-Setälä K., Fisher E.A., Chen X., Chajek-Shaul T., Hayek T., Zechner R., Walsh A., Ramakrishnan R., Ginsberg H.N., Breslow J.L. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 90:1992;1889-1900.
46. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 75:1985;384-390.
47. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., Goldstein J.L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 265:1990;10771-10779.
48. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 266:1991;18259-18267.
49. De Silva H.V., Lauer S.J., Wang J., Simonet W.S., Weisgraber K.H., Mahley R.W., Taylor J.M. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 269:1994;2324-2335.
50. Windler E., Havel R.J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 26:1985;556-565.
51. Weisgraber K.H., Mahley R.W., Kowal R.C., Herz J., Goldstein J.L., Brown M.S. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 265:1990;22453-22459.
52. Simonet W.S., Bucay N., Pitas R.E., Lauer S.J., Taylor J.M. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem. 266:1991;8651-8654.
53. Shachter N.S., Ebara T., Ramakrishnan R., Steiner G., Breslow J.L., Ginsberg H.N., Smith J.D. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein CI. J Clin Invest. 98:1996;846-855.
54. Sharrett A.R., Chambless L.E., Heiss G., Paton C.C., Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 15:1995;2122-2129.
55. Bjorkegren J., Hamsten A., Milne R.W., Karpe F. Alterations of VLDL composition during alimentary lipidemia. J Lipid Res. 38:1997;301-314.
56. Alaupovic P., Knight-Gibson C., Wang C.-S., Downs D., Koren E., Brewer H.B. Jr, Gregg R.E. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res. 32:1991;9-19.
57. Fisher W.R. Heterogeneity of plasma low density lipoproteins manifestations of the physiologic phenomenon in man . Metabolism. 32:1983;283-291.
58. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 23:1982;97-104.
59. Austin M.A., King M.-C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 82:1990;495-506.
60. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
61. Austin M.A., Hokanson J.E., Brunzell J.D. Characterization of low-density lipoprotein subclasses methodologic approaches and clinical relevance . Curr Opin Lipidol. 5:1994;395-403.
62. Chapman M.J., Guerin M., Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 19:(suppl A):1998;A24-A30.
63. McNamara J.R., Small D.M., Li Z., Schaefer E.J. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res. 37:1996;1924-1935.
64. Campos H., Genest J.J. Jr, Blijlevens E., McNamara J.R., Jenner J.L., Ordovas J.M., Wilson P.W.F., Schaefer E.J. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 12:1992;187-195.
65. Crouse J.R., Parks J.S., Schey H.M., Kahl F.R. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 26:1985;566-574.
66. Griffin B.A., Freeman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions relative contribution of small, dense LDL to coronary heart disease risk . Atherosclerosis. 106:1994;241-253.
67. Lahdenpera S., Syvanne M., Kahri J., Taskinen M.R. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease importance of serum triglycerides . Diabetologia. 39:1996;453-461.
68. Watts G.F., Mandalia S., Brunt J.N., Slavin B.M., Coltart D.J., Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 42:1993;1461-1467.
69. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:1996;2146-2153.
70. Superko H.R. Beyond LDL cholesterol reduction. Circulation. 94:1996;2351-2354.
71. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 95:1997;69-75.
72. Vega G.L., Clark L.T., Tang A.M., Marcovina S., Grundy S.M., Cohen J.C. Hepatic lipase activity is lower in African-American men than in white American men effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC) . J Lipid Res. 39:1998;228-232.
73. Zambón A., Austin M.A., Brown B.G., Hokanson J.E., Brunzell J.D. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 13:1993;147-153.
74. Watson T.D., Caslake M.J., Freeman D.J., Griffin B.A., Hinnie J., Packard C.J., Shepherd J. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb. 14:1994;902-910.
75. Tan C.E., Foster L., Caslake M.J., Bedford D., Watson T.D., McConnell M., Packard C.J., Shepherd J. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vasc Biol. 15:1995;1839-1848.
76. Zambón A., Deeb S.S., Hokanson J.E., Brown B.G., Brunzell J.D. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol. 18:1998;1723-1729.
77. Hokanson J.E., Brunzell J.D., Jarvik G.P., Wijsman E.M., Austin M.A. Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet. 64:1999;608-618.
78. Tribble D.L. Lipoprotein oxidation in dyslipidemia insights into general mechanisms affecting lipoprotein oxidative behavior . Curr Opin Lipidol. 6:1995;196-208.
79. Anber V., Griffin B.A., McConnell M., Packard C.J., Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 124:1996;261-271.
80. Bjornheden T., Babyi A., Bondjers G., Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 123:1996;43-56.
81. Miller N.E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 113:(2 pt 2):1987;589-597.
82. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62:1977;707-714.
83. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D. Jr, Jacobs D.R. Jr, Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
84. Buring J.E., O'Connor G.T., Goldhaber S.Z., Rosner B., Herbert P.N., Blum C.B., Breslow J.L., Hennekens C.H. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation. 85:1992;22-29.
85. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 5:1994;339-349.
86. Le N.A., Ginsberg H.N. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism. 37:1988;614-617.
87. Kuusi T., Saarinen P., Nikkilä E.A. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis. 36:1980;589-593.
88. Kinnunen P.K.J., Virtanen J.A., Vainio P. Lipoprotein lipase and hepatic endothelial lipase their role in plasma lipoprotein metabolism . Gotto A.M. Jr, Paoletti R. Atherosclerosis Reviews. 1983;65-105 Raven Press, New York.
89. Busch S.J., Barnhart R.L., Martin G.A., Fitzgerald M.C., Yates M.T., Mao S.J.T., Thomas C.E., Jackson R.L. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem. 269:1994;16376-16382.
90. Havel R.J., Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 332:1995;1491-1498.
91. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 81:(4A):1998;26B-31B.
92. Vega G.L., Grundy S.M. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 10:1990;668-671.
93. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., Tanaka A., Tada N., Nakamura H., Campos E., Havel R.J. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apoA-I immunoaffinity mixed gels. Clin Chim Acta. 223:1993;53-71.
94. Leary E.T., Wang T., Baker D.J., Cilla D.D., Zhong J., Warnick G.R., Nakajima K., Havel R.J. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem. 44:1998;2490-2498.
95. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., Schaefer E.J. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin Chem. 44:(6 pt 1):1998;1224-1232.
96. Alaupovic P. David Rubinstein Memorial Lecture the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins . Can J Biochem. 59:1981;565-579.
97. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., Azen S.P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 81:1990;470-476.
98. Avogaro P., Bon G.B., Cazzolato G., Rorai E. Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis. 37:1980;69-76.
99. Tatami R., Mabuchi H., Ueda K., Ueda R., Haba T., Kametani T., Ito S., Koizumi J., Ohta M., Miyamoto S., Nakayama A., Kanaya H., Oiwake H., Genda A., Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 64:1981;1174-1184.
100. Kameda K., Matsuzawa Y., Kubo M., Ishikawa K., Maejima I., Yamamura T., Yamamoto A., Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 51:1984;241-249.
101. Reardon M.F., Nestel P.J., Craig I.H., Harper R.W. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 71:1985;881-888.
102. Steiner G., Schwartz L., Shumak S., Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 75:1987;124-130.
103. Krauss R.M., Lindgren F.T., Williams P.T., Kelsey S.F., Brensike J., Vranizan K., Detre K.M., Levy R.I. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Am J Cardiol. 2:1987;62-66.
104. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:1993;2762-2770.
105. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashen-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240.
106. Alaupovic P., Mack W.J., Knight-Gibson C., Hodis H.N. The role of triglyceride-rich lipoprotein families in the progress of atherosclerotic lesions are determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 17:1997;715-722.
107. Hodis H.N., Mack W.J., Azen S.P., Alaupovic P., Pogoda J.M., LaBree L., Hemphill L.C., Kramsch D.M., Blankenhorn D.H. Triglyceride- and cholesterol-rich lipoproteins have differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49.
108. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Stampfer M.J., Pfeffer M.A., Braunwald E. New lipoprotein predictors of recurrent coronary events VLDL particle concentration, VLDL lipid content, and apolipoprotein CIII and E . Circulation. 98:(suppl S):1998;1-791.
109. Gofman J.W., Young W., Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 34:1966;679-697.
110. Krauss R.M. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J. 113:(2 pt 2):1987;578-582.
111. Freedman D.S., Otvos J.D., Jeyarajah E.J., Barboriak J.J., Anderson A.J., Walker J.A. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 18:1998;1046-1053.
112. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1996;1179-1184.
113. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Mänttäri M., Heinonen O.P., Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 85:1992;37-45.
114. Zambón S., Manzato E., Solini A., Sambataro M., Brocco E., Sartore G., Crepaldi G., Nosadini R. Lipoprotein abnormalities in non-insulin-dependent diabetic patients with impaired extrahepatic insulin sensitivity, hypertension, and microalbuminuria. Arterioscler Thromb. 14:1994;911-916.
115. Reaven G.M. Insulin resistance and its consequences non-insulin dependent diabetes mellitus and coronary heart disease . LeRoith D., Taylor S.I., Ofefsky J.M. Diabetes Mellitus A Fundamental and Clinical Text . 1996;509-519 Lippincott-Raven Publishers, Philadelphia.
116. Grundy S.M. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation. 95:1997;1-4.